GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zhongyuan Union Cell & Gene Engineering Corp Ltd (SHSE:600645) » Definitions » Net Cash per Share

Zhongyuan Union Cell & Gene Engineering (SHSE:600645) Net Cash per Share : ¥-0.16 (As of Mar. 2025)


View and export this data going back to 1993. Start your Free Trial

What is Zhongyuan Union Cell & Gene Engineering Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Zhongyuan Union Cell & Gene Engineering's Net Cash per Share for the quarter that ended in Mar. 2025 was ¥-0.16.

The historical rank and industry rank for Zhongyuan Union Cell & Gene Engineering's Net Cash per Share or its related term are showing as below:

SHSE:600645's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 3.86
* Ranked among companies with meaningful Price-to-Net-Cash only.

Zhongyuan Union Cell & Gene Engineering Net Cash per Share Historical Data

The historical data trend for Zhongyuan Union Cell & Gene Engineering's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhongyuan Union Cell & Gene Engineering Net Cash per Share Chart

Zhongyuan Union Cell & Gene Engineering Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.04 -0.80 -0.72 -0.31 -0.28

Zhongyuan Union Cell & Gene Engineering Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.40 -0.53 -0.48 -0.28 -0.16

Competitive Comparison of Zhongyuan Union Cell & Gene Engineering's Net Cash per Share

For the Biotechnology subindustry, Zhongyuan Union Cell & Gene Engineering's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zhongyuan Union Cell & Gene Engineering's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zhongyuan Union Cell & Gene Engineering's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Zhongyuan Union Cell & Gene Engineering's Price-to-Net-Cash falls into.


;
;

Zhongyuan Union Cell & Gene Engineering Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Zhongyuan Union Cell & Gene Engineering's Net Cash per Share for the fiscal year that ended in Dec. 2024 is calculated as

Net Cash per Share (A: Dec. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1524.991-1589.881-63.978)/467.949
=-0.28

Zhongyuan Union Cell & Gene Engineering's Net Cash per Share for the quarter that ended in Mar. 2025 is calculated as

Net Cash per Share (Q: Mar. 2025 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(1551.412-1566.092-61.502)/467.949
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Zhongyuan Union Cell & Gene Engineering  (SHSE:600645) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Zhongyuan Union Cell & Gene Engineering Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Zhongyuan Union Cell & Gene Engineering's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Zhongyuan Union Cell & Gene Engineering Business Description

Traded in Other Exchanges
N/A
Address
45 East of Tianjin Airport Economic Zone nine, Tianjin, CHN, 300304
Zhongyuan Union Cell & Gene Engineering Corp Ltd is engaged in stem cell technology research, as well as detection and storage sources of stem cells in China. The company insists on the core strategy upon dual-core development of 'cell + gene' with the major businesses covering various cell storage businesses of newborns and adults; the preparation and storage of cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental pluripotent stem cells, adipose-derived stem cells and immune cells; genetic testing services relating to children's genes.
Executives
Li De Fu Director
Wang Xue Jun senior management
Wang Yong Director
Li Hai Bin Director
He Wei senior management
Li Qiang senior management
Wu Ming Yuan Director
Wang Hui Director
Huang Jia Xue senior management
Cao Hai Feng Director
Han Yue E Director
Liu Yong Jun senior management
Cui Jing Xue Supervisors
Yang Guang Xing senior management
Meng Zhi Hong senior management

Zhongyuan Union Cell & Gene Engineering Headlines

No Headlines